SCHEMBL10921114

SCHEMBL10921114

O=C(c1ccc([N+](=O)[O-])cc1)c1c[nH]c(=O)[nH]1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 2/20 0.51
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
CES1 P23141 2/20 0.49
MAPK1 P28482 2/20 0.47
POLB P06746 1/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
ALDH1A1 P00352 2/20 0.46
TSHR P16473 1/20 0.46
MAPT P10636 1/20 0.45
CES2 O00748 1/20 0.44
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10924690 0.77 HTT (0.39) LMNAGAAPOLBCA1CA2
SCHEMBL7487387 0.76 ALDH1A1 (0.48) SRD5A2GAAL3MBTL1TDP1ALDH1A1
SCHEMBL6326821 0.76 SRD5A2 (0.56) SRD5A2LMNAGAAL3MBTL1CES1
SCHEMBL975118 0.75 SRD5A2 (0.83) SRD5A2LMNAGAAL3MBTL1CES1
SCHEMBL10723714 0.75 SRD5A2 (0.83) SRD5A2LMNAGAAL3MBTL1CES1
SCHEMBL29360098 0.71 IGFBP3 (0.47) GAAL3MBTL1POLBCA1CA2
SCHEMBL10920493 0.71 PDE4A (0.60) SRD5A2LMNAGAAL3MBTL1CES1
SCHEMBL29191028 0.71 SRD5A2 (0.63) SRD5A2LMNAGAAL3MBTL1CES1
SCHEMBL28914440 0.70 MAPK1 (0.85) SRD5A2LMNAGAAL3MBTL1CES1
SCHEMBL6231410 0.70 LMNA (0.51) SRD5A2LMNAGAAL3MBTL1CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3131545-B1 USE OF ENOXIMONE IN THE TREATMENT OF ATOPIC IMMUNE-RELATED DISORDERS, IN PHARMACEUTICAL COMPOSITIONS AS WELL AS IN PHARMACEUTICAL PREPARATIONS BREAKTHROUGH MEDICAL RES B V (NL) 2024-05-29 EP disclosed
US-20230270724-A1 PDE3 inhibitors for treating viral infections BREAKTHROUGH MEDICAL RESEARCH B.V. (NL) 2023-08-31 US disclosed
CN-116171151-A PDE3 inhibitors for the treatment of viral infections 突破医学研究公司 2023-05-26 CN disclosed
EP-4181887-A1 PDE3 INHIBITORS FOR TREATING VIRAL INFECTIONS Breakthrough Medical Research B.V. (NL) 2023-05-24 EP disclosed
WO-2022018085-A1 PDE3 INHIBITORS FOR TREATING VIRAL INFECTIONS BREAKTHROUGH MEDICAL RESEARCH B.V. (NL) 2022-01-27 WO disclosed
EP-3763365-A1 AROYLIMIDAZOLONES FOR THE TREATMENT OF THAUMETOPOEA EXPOSURE Breakthrough Medical Research B.V. (NL) 2021-01-13 EP disclosed
US-10071077-B2 Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation BREAKTHROUGH MEDICAL RESEARCH B.V. (NL) 2018-09-11 US disclosed
EP-3131545-A2 USE OF ENOXIMONE IN THE TREATMENT OF ATOPIC IMMUNE-RELATED DISORDERS, IN PHARMACEUTICAL COMPOSITION AS WELL AS IN PHARMACEUTICAL PREPARATION Breakthrough Medical Research B.V. (NL) 2017-02-22 EP disclosed
US-20170035735-A1 Use Of Enoximone In The Treatment Of Atopic Immune-Related Disorders, In Pharmaceutical Composition As Well As In Pharmaceutical Preparation BREAKTHROUGH MEDICAL RESEARCH B.V. (NL) 2017-02-09 US disclosed
WO-2015160249-A2 USE OF ENOXIMONE IN THE TREATMENT OF ATOPIC IMMUNE-RELATED DISORDERS, IN PHARMACEUTICAL COMPOSITION AS WELL AS IN PHARMACEUTICAL PREPARATION BREAKTHROUGH MEDICAL RESEARCH B.V. (NL) 2015-10-22 WO disclosed
EP-0058435-B1 NOVEL 4-AROYLIMIDAZOL-2-ONES MERRELL DOW PHARMACEUTICALS INC. (US) 1986-12-30 EP disclosed
EP-0059948-B1 NOVEL AROYLIMIDAZOLONES MERRELL DOW PHARMACEUTICALS INC. (US) 1985-11-13 EP disclosed
US-4405635-A HYPOTENSIVE, CARDIOTONIC, BRONCHODILATOR, ANTICOAGULANT, AND MUSCLE RELAXANT AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1983-09-20 US disclosed
EP-0058435-A2 Novel 4-aroylimidazol-2-ones MERRELL DOW PHARMACEUTICALS INC. (US) 1982-08-25 EP disclosed